newsfilter
← Latest News
Earnings Call Transcripts·

AI Panel - NOVABRIDGE BIOSCIENCES

  • Financial Performance:

    • No specific quarterly revenue, earnings, or cash flow figures were disclosed in this R&D-focused session.
    • Management highlighted cost optimization in manufacturing (best-in-class COGS excluding royalties) and automation.
    • Identified $11 billion in third-party spend as a key area for potential reduction via AI tools, noting impact already exceeded internal expectations for the current year.
    • Data asset valued at over 150 petabytes of research data, described as equivalent to 40 million years of 4K Netflix streaming.
  • Guidance and Future Outlook:

    • Forecasting compounding productivity gains across the R&D portfolio as AI integration scales.
    • Targeting a reduction in program start-to-candidate time from 3-4 years to under 2.5 years, with "AI-first" programs achieving a one-year cycle time.
    • Expecting to calculate improvements in safety attrition rates within "a few years" based on current generative chemistry pipelines.
    • Long-term goal to shift from sequential R&D processes to continuous learning loops that traverse organizational boundaries.
  • Business Segments and Product Lines:

    • Discovery: Leveraging "AI-first" generative chemistry to explore wider chemical spaces and identify novel targets; currently advancing three novel neurodegeneration targets to later-stage programs.
    • Development: Using AI for site selection (accelerated enrollment by six months for V1P) and protocol design; 90% of clinical study report content is now AI-assisted, reducing review time by 25%.
    • Collaborations: Strategic partnerships with Isomorphic Labs (protein folding), Relation (clinical tissue data), Chai (prediction software), and Decifex (digitized pathology slides for safety).
    • Manufacturing: Accelerating deployment of robotics and automation to drive efficiency in sites like RLT.
  • Market and Competitive Landscape:

    • Novartis differentiates via decades of organized, harmonized internal data (Data42) and deep disease-specific knowledge rather than proprietary compute or base models.
    • Competitive advantage stems from the ability to access unique, non-replicable historical clinical datasets (e.g., KANTOS trial) and cross-disease learning pools.
    • Management asserts that while technology is a "level playing field," the speed of adoption and data orchestration provide a durable lead.
    • Acknowledges that other pharma peers are catching up on data organization, but Novartis claims a head start due to a decade-long preparation starting around 2017.
  • Risks and Challenges:

    • Data Privacy & Security: Concerns regarding external data ingestion; mitigated by keeping models behind the firewall, ensuring fine-tuned models remain proprietary, and strict security testing.
    • Regulatory Uncertainty: Endpoints and predictive safety models require regulatory validation and acceptance (e.g., VHT, AI-enhanced EKGs).
    • Scientific Limitations: AI cannot currently "crack" diseases with no prior trial history or biological understanding; human judgment remains critical to distinguish correlation from causality.
    • Publication Strategy: Deliberate delays in disclosing new target identification to prevent fast-follower competitors from catching up.
  • Management Commentary and Tone:

    • Tone is confident and conviction-driven regarding the "next five years" of R&D transformation.
    • Emphasizes a "demand-driven" culture where adoption is fueled by utility rather than mandates; notes high enthusiasm among staff (e.g., clinical reviewers).
    • Leadership (Fiona Marshall, Max Lawson, Christian Diehl) projects a shift from tool-based usage to process reimagining (e.g., "lab-in-the-loop").
    • Rejects the notion of building a single "world model," preferring disease-specific foundational models.
  • Analyst Questions and Answers:

    • Data Accessibility: Data42 is accessible to all employees (e.g., B-cell pool insights shared across oncology, immunology, neuro) but requires scientific purpose and approval for privacy compliance.
    • Novelty of AI: Confirmed AI is generating novel targets and molecules not found via traditional high-throughput screening; 3 novel neuro targets are advancing.
    • Probability of Success (POS): Focus on "safety by design" to predict failure early and simulating trials to improve patient recruitment accuracy; endpoint sophistication improving via AI.
    • Talent Retention: AI viewed as a stimulus for creativity, freeing scientists from administrative tasks (e.g., slide creation) and enabling cross-functional upskilling (e.g., medicinal chemists doing computational work).
    • Collaboration: Increased openness to collaborate with hospitals and academic institutes (e.g., Helmholtz) for data access, though competitive areas may see delayed disclosure.
  • Other Key Points:

    • AI Fluency: Novartis has rolled out AI fluency training across the entire company in three tiers to ensure broad capability.
    • Compute Strategy: No constraint on in-house compute; utilizes internal high-performance environments and bursts to cloud (e.g., AWS) for spikes; all open-source models ingested into the stack within 24 hours if security-passed.
    • Intellectual Property: Using generative AI to build dense "onion-like" patent estates around novel compound series.
    • Validation: Emphasizes the necessity of "lab-in-the-loop" assays (cell-based or in vivo) to validate AI outputs before clinical progression.
Company
NOVABRIDGE BIOSCIENCES
Keywords
NOVABRIDGE BIOSCIENCES